ACRS (Aclaris Therapeutics, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by ACRS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-04 | Roland Wilhelm Kolbeck | Chief Scientific Officer | MIXED | — | — |
| 2026-06-08 | MAXINE GOWEN | Director | M | — | — |
| 2026-06-08 | VINCENT MILANO | Director | M | — | — |
| 2026-06-08 | Anand Mehra | Director | M | — | — |
| 2026-06-08 | William D. Humphries | Director | M | — | — |
| 2026-06-08 | Christopher P. Molineaux | Director | M | — | — |
| 2026-06-08 | ANDREW N SCHIFF | Director | M | — | — |
| 2026-05-05 | Jesse Wayne Hall | Chief Medical Officer | MIXED | — | — |
| 2026-04-27 | Braden Michael Leonard | 10%+ Owner | Sell | — | — |
| 2026-03-03 | Kevin Balthaser | Chief Financial Officer | MIXED | — | — |
| 2026-02-06 | Roland Wilhelm Kolbeck | Chief Scientific Officer | A | — | — |
| 2026-02-06 | James Loerop | Chief Business Officer | A | — | — |
| 2026-02-06 | Kevin Balthaser | Chief Financial Officer | A | — | — |
| 2026-02-06 | Hugh M. Davis | President and COO | A | — | — |
| 2026-02-06 | Neal Walker | CEO | A | — | — |
| 2026-02-06 | Jesse Wayne Hall | Chief Medical Officer | A | — | — |
| 2026-02-05 | James Loerop | Chief Business Officer | MIXED | — | — |
| 2026-02-05 | Kevin Balthaser | Chief Financial Officer | MIXED | — | — |
| 2026-02-05 | James Loerop | Chief Business Officer | MIXED | — | — |
| 2026-02-05 | Hugh M. Davis | President and COO | M | — | — |
| 2026-02-05 | Neal Walker | CEO | MIXED | — | — |
| 2026-02-03 | James Loerop | Chief Business Officer | F | — | — |
| 2026-02-03 | Kevin Balthaser | Chief Financial Officer | MIXED | — | — |
| 2026-02-03 | James Loerop | Chief Business Officer | F | — | — |
| 2026-01-05 | Neal Walker | CEO | MIXED | — | — |
| 2026-01-05 | James Loerop | Chief Business Officer | MIXED | — | — |
| 2026-01-05 | Kevin Balthaser | Chief Financial Officer | MIXED | — | — |
| 2025-12-04 | Hugh M. Davis | President and COO | M | — | — |
| 2025-08-05 | Roland Wilhelm Kolbeck | Chief Scientific Officer | A | — | — |
| 2025-06-09 | VINCENT MILANO | Director | M | — | — |
| 2025-06-09 | Christopher P. Molineaux | Director | M | — | — |
| 2025-06-09 | Anand Mehra | Director | M | — | — |
| 2025-06-09 | William D. Humphries | Director | M | — | — |
| 2025-06-09 | MAXINE GOWEN | Director | M | — | — |
| 2025-06-09 | ANDREW N SCHIFF | Director | M | — | — |
| 2025-05-05 | Jesse Wayne Hall | Chief Medical Officer | A | — | — |
| 2025-05-05 | Neal Walker | CEO | MIXED | — | — |
| 2025-04-03 | Neal Walker | CEO | MIXED | — | — |
| 2025-03-04 | Neal Walker | CEO | MIXED | — | — |
| 2025-03-04 | Joseph Monahan | Chief Scientific Officer | MIXED | — | — |
| 2025-03-04 | Kevin Balthaser | Chief Financial Officer | MIXED | — | — |
| 2025-02-04 | Joseph Monahan | Chief Scientific Officer | MIXED | — | — |
| 2025-02-04 | Neal Walker | INTERIM CEO | MIXED | — | — |
| 2025-02-04 | Kevin Balthaser | Chief Financial Officer | MIXED | — | — |
| 2025-02-04 | Hugh M. Davis | President and COO | A | — | — |
| 2025-02-04 | James Loerop | Chief Business Officer | MIXED | — | — |
| 2025-01-03 | Kevin Balthaser | Chief Financial Officer | MIXED | — | — |
| 2025-01-03 | James Loerop | Chief Business Officer | MIXED | — | — |
| 2025-01-03 | Joseph Monahan | Chief Scientific Officer | MIXED | — | — |
| 2025-01-03 | Neal Walker | INTERIM CEO | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 13,950,000 | — |
| — | Director | 4,191,397 | — |
| — | 10%+ Owner | 4,101,997 | — |
| — | — | 3,159,165 | — |
| — | Director | 2,637,976 | — |
| — | 10%+ Owner | 2,586,190 | — |
| — | 10%+ Owner | 2,469,552 | — |
| — | 10%+ Owner | 2,289,480 | — |
| — | 10%+ Owner | 2,125,769 | — |
| — | 10%+ Owner | 1,931,727 | — |
| — | CEO | 1,562,497 | — |
| — | 10%+ Owner | 1,411,628 | — |
| — | 10%+ Owner | 1,166,959 | — |
| — | 10%+ Owner | 1,072,775 | — |
| — | Director | 571,471 | — |
| — | Director | 459,995 | — |
| — | Chief Scientific Officer | 282,188 | — |
| — | Chief Scientific Officer | 273,355 | — |
| — | Chief Reg & Develop Officer | 272,163 | — |
| — | Chief Financial Officer | 201,883 | — |
| — | Chief Financial Officer | 188,130 | — |
| — | Chief Business Officer | 188,008 | — |
| — | Chief Legal Officer | 153,114 | — |
| — | Chief Medical Officer | 147,447 | — |
| — | 10%+ Owner | 79,635 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ACRS quote page; the site-wide leaderboard is on the insider transactions hub.